. Author manuscript; available in PMC: 2015 Apr 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):535–541. doi: 10.1097/QAI.0000000000000071

Table 1.

Baseline characteristics of subjects

	LPV/r (n=91^*)	NNRTI (n=92^*)	P-value^†
Age, years	3.1 (2.4 to 4.3)	3.1 (2.4 to 4.7)	0.63
Female	44 (48%)	45 (48%)	0.53
WHO Stage			0.82
I	64 (70%)	70 (76%)
II	19 (21%)	16 (17%)
III	2 (2%)	1 (1%)
IV	6 (7%)	5 (5%)
ART-status			0.55
ART-naïve	64 (70%)	65 (71%)
ART-experienced	27 (29%)	27 (29%)
CD4 number, cells/μl
ART-naïve	582 (597 to 969)	593 (389 to 788)	0.89
ART-experienced	1275 (861 to 1885)	1099 (802 to 1906)	0.59
CD4 Percentage
ART-naïve	17 (12 to 23)	16 (11 to 23)	0.77
ART-experienced	31 (27 to 38)	30 (24 to 37)	0.60
HIV RNA Level, log(copies/ml)
ART-naïve	5.3 (4.8 to 5.9)	5.5 (4.8 to 5.9)	0.75
ART-experienced	All BLD	All BLD	-

Excludes the 2 children who withdrew or died before initiating study drugs.

^†

Student's T-Test or Chi-square.

Values are medians (interquartile range) or number (percentage); LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside-reverse-transcriptase-inhibitor; BLD, below level of detection, 400 copies/ml.